92.61
+2.91%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About LivaNova
From its filings with the US Securities and Exchange Commission
LivaNova is based in Gloucester and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker LIVN. The SEC classifies its business as electromedical & electrotherapeutic apparatus. In the fiscal year to 31 December 2025, it reported revenue of $1.39bn and a net loss of $242.5m. At that date it held total assets of $2.61bn and shareholders' equity of $1.20bn.
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. “Other” includes non-allocated corporate expenses and the non-cannula results of the Company’s former ACS segment, which was wound down during 2024.
LivaNova’s Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including HLMs, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, and provides services related to certain of these products. In particular, the Cardiopulmonary segment includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies and sensing technology for data-driven decision-making during CPB procedures.
CPB is frequently utilized in various heart-related medical procedures and allows surgical teams to oxygenate and circulate a patient’s blood, providing the necessary conditions for the surgeon to operate on the heart. Medical procedures most commonly requiring CPB include traditional coronary artery bypass grafting and valve surgeries. LivaNova’s products enable CPB for neonatal, pediatric, and adult patients.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Oct 2015
- Employees
- 3,300
- Website
- livanova.com/home.action ↗
- Head office
- 5220 VALIANT COURT, GLOUCESTER
- Incorporated in
- X0
- Classification
- Electromedical & Electrotherapeutic Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. William KozyIndependent Chairman of the Board, since 2018$827,104
- Mr. Vladimir MakatsariaChief Executive Officer, Director, since 2024$9.7m
- Mr. Alex ShvartsburgChief Financial Officer$2.8m
- Ms. Stephanie BoltonPresident, Global Epilepsy
- Mr. Franco PolettiPresident, Cardiopulmonary Business Unit$2.2m
- Mr. Michael HutchinsonSenior Vice President, Chief Legal Officer, Company Secretary$2.4m
- Dr. Ahmet TezelSenior Vice President, Chief Innovation Officer$2.8m
- Mr. Donald ZurbayDirector
- Mr. J. Christopher BarryIndependent Director$281,808
- Mr. Francesco BianchiIndependent Director$285,390
- Dr. Sharon O'KaneIndependent Director$287,335
- Ms. Susan PodlogarIndependent Director$137,022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 62
- Environment
- 53
- Social
- 73
- Governance
- 59
- Direct emissions (scope 1)
- 14,173.3 t
- Energy emissions (scope 2)
- 10,425.58 t
- Value chain emissions (scope 3)
- 728.14 t
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- LivaNova PLC has several strengths that contribute to its competitive advantage in the industry. Firstly, the company has a strong portfolio of innovative medical technology products, allowing it to meet the diverse needs of patients and healthcare professionals. This enables LivaNova to stay ahead of its competitors and maintain a strong market position. Secondly, the company has a global presence, with operations in various countries, which provides it with access to a wide customer base and opportunities for growth. Additionally, LivaNova has a talented and experienced workforce, enabling it to develop and deliver high-quality products and services.
Weaknesses
- Despite its strengths, LivaNova PLC also faces certain weaknesses that need to be addressed. One major weakness is the company's heavy dependence on a few key products for a significant portion of its revenue. This exposes LivaNova to risks such as market fluctuations and potential product obsolescence. Another weakness is the company's limited presence in emerging markets, which hinders its ability to tap into the growing demand for medical technology in these regions. Moreover, LivaNova has faced challenges in effectively integrating acquired businesses, resulting in potential operational inefficiencies.
Opportunities
- LivaNova PLC has several opportunities that can be capitalized on to drive growth and profitability. The increasing prevalence of chronic diseases and the aging population present a significant opportunity for the company to expand its product offerings and enter new markets. Additionally, the growing demand for minimally invasive surgeries and advanced medical treatments provides LivaNova with the chance to develop innovative solutions that cater to these trends. Furthermore, partnerships and collaborations with healthcare organizations and research institutions can enhance LivaNova's research and development capabilities, leading to new breakthrough products.
Threats
- LivaNova PLC operates in an industry that is characterized by intense competition and regulatory challenges, posing threats to its business. The presence of strong competitors with established market positions and significant resources can make it difficult for LivaNova to gain market share. Moreover, the company is subject to strict regulations and compliance requirements, which can impact its ability to introduce new products and expand into certain markets. Additionally, economic downturns and fluctuations in healthcare spending can affect the demand for LivaNova's products and services, presenting a potential threat to its financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.